Compare AXT Inc (AXTI) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AXT Inc vs Quest Diagnostics Inc — how do they compare? AXT Inc trades at $79 (market cap $4.83B), while Quest Diagnostics Inc trades at $237.63 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 5.4× AXT Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while AXT Inc pays none. Which is the better fit depends on your goals.
| AXTI | DGX | |
|---|---|---|
Market Cap | $4.83B | $26.21B |
Sector | Technology | Health |
52-Week High | $140.83 | $238.50 |
52-Week Low | $2.05 | $173.49 |
Enterprise Value | $4.50B | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXTI trades at $79.75, up 8.05% on the day, reflecting strong momentum following Q2 2026 earnings that beat estimates with EPS of $0.19 versus $0.07 expected. The stock is in a bullish technical trend, with support near $72 and resistance at $79. Revenue surged to $126 million in 2026, driving a net profit of $4 million and margin expansion to 3.23%, supported by record indium phosphide demand for AI data centers.
Outlook is positive given AI-driven demand and capacity expansion, but high valuation ratios (P/S 30.53) and negative operating cash flow pose risks. Analyst consensus is bullish with a $72.50 price target, though the current price exceeds it, suggesting near-term consolidation may occur.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
